This refresh
Data-driven refresh June 23, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow), ranked across a 5216-ticker universe covering every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (2553 passed the market-cap / liquidity screen; financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top Picks — quality compounders at a fair price
1. INCY — Incyte Corporation · score 90.6
Biotechnology · price $104.40 · 1Y $110.26 · 5Y $161.43 · 10Y $239.47
FCF $1.4b C+ · Rev +21.2% A- · D/E 0.01 A · P/E 14.7x A- · PEG 0.36 A
Why now. Incyte Corporation is a compelling growth investment due to its robust product lineup, particularly JAKAFI, which drives its 21.2% revenue growth and $1.4B free cash flow, all while maintaining a 14.7 P/E ratio and 0.36 PEG ratio, positioning it for sustained compounding as it expands its therapeutics portfolio, with the crux being its ability to maintain this growth trajectory.
Moat. Incyte's durable edge stems from its strong portfolio of therapeutics, including JAKAFI and ICLUSIG, which provide a cost advantage through their efficacy and patient retention, contributing to its 25.5% ROE, a result of pricing power from category leadership in specific disease treatments, making it challenging for competitors to quickly replicate its success.
Risk. The primary threat to Incyte's growth is the potential for increased competition in the biopharmaceutical market, particularly for its key products like JAKAFI, which could lead to margin contraction, as evidenced by its 0.79 beta, indicating some market sensitivity, and the bear case would be confirmed if Incyte fails to expand its product portfolio effectively, leading to a decline in its 26.7% profit margin.
Horizon. 1-3 yr $110.26 (analyst consensus (n=23)) — fundamentals + valuation re-rating. 5 yr $161.43 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $239.47 if current growth sustains into durable earnings power.
2. DOCS — Doximity, Inc. · score 90.1
Health Information Services · price $20.48 · 1Y $25.42 · 5Y $37.22 · 10Y $55.21
FCF $326m C · Rev +13.1% B+ · D/E 0.01 A · P/E 20.9x B+ · PEG 0.59 A-
Why now. Doximity's bull case rests on its ability to compound growth through its personalized newsfeed and workflow tools like Ask and Scribe, with a 20.9 P/E ratio, $326m in free cash flow, and 30.4% profit margin, all of which suggest a high-quality growth franchise. The 13.1% revenue growth rate and 0.59 PEG ratio indicate that this growth is not only occurring but is also reasonably valued. The crux of this thesis is that Doximity can continue to leverage its platform to drive engagement and revenue growth among medical professionals.
Moat. Doximity's durable edge comes from its network effect, where the value of its platform increases as more medical professionals join and contribute to the community, creating a self-reinforcing cycle. The 20.6% ROE suggests that Doximity has pricing power, which is likely due to its category leadership in providing a personalized newsfeed and workflow tools to medical professionals. This advantage is difficult for competitors to replicate quickly, as it requires a significant investment in building a large and engaged community of users.
Risk. The bear case against Doximity is that its growth may slow down due to increasing competition from other digital platforms targeting medical professionals, with a 1.29 beta indicating higher volatility. The $3.7b market cap and 20.9 P/E ratio may also be at risk if the company's revenue growth decelerates, which could be confirmed by a decline in the 13.1% revenue growth rate. If Doximity's growth slows down significantly, it could break the bull thesis and lead to a re-rating of the stock.
Horizon. 1-3 yr $25.42 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $37.22 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $55.21 if current growth sustains into durable earnings power.
3. INTU — Intuit Inc. · score 89.9
Software - Application · price $258.05 · 1Y $488.17 · 5Y $714.73 · 10Y $1,060
FCF $7.8b B+ · Rev +15.6% B+ · D/E 0.33 B · P/E 15.7x A- · PEG 0.67 A-
Why now. The bull case for INTU rests on its ability to compound growth through its QuickBooks services, which have driven a 15.6% revenue growth rate, with a 21.9% profit margin and $7.8B in free cash flow, positioning the company for sustained expansion. This growth is further supported by a 0.67 PEG ratio, indicating the stock's price is reasonable relative to its growth prospects. The crux of this thesis is the persistence of this growth, driven by the stickiness of QuickBooks for small and mid-market businesses.
Moat. INTU's durable edge stems from its category leadership in financial and business management online services, particularly through QuickBooks, which creates a switching cost for its customers. The company's 22.2% ROE is a testament to its pricing power, derived from its dominant position in the market. This advantage is further reinforced by the network effects of its Mailchimp marketing automation and customer relationship management services, making it difficult for competitors to replicate quickly.
Risk. The bear case against INTU is centered on its valuation, with a 15.7 P/E ratio that may be considered elevated, especially if revenue growth decelerates. The company's 0.96 beta also suggests it may be more volatile than the broader market, increasing the risk for investors. A concrete signal that would confirm the bear case is a significant decline in revenue growth, potentially triggered by increased competition in the financial management and payments sector, which would undermine the bull thesis.
Horizon. 1-3 yr $488.17 (analyst consensus (n=32)) — fundamentals + valuation re-rating. 5 yr $714.73 at ~23% CAGR — compounding case rests on the competitive position widening. 10 yr $1,060 if current growth sustains into durable earnings power.
4. ADBE — Adobe Inc. · score 89.8
Software - Application · price $197.43 · 1Y $282.27 · 5Y $413.27 · 10Y $613.06
FCF $10.3b A- · Rev +10.5% B · D/E 0.61 C+ · P/E 11.3x A · PEG 0.53 A-
Why now. The bull case for ADBE rests on its ability to compound growth through its Digital Media segment, which serves a wide range of customers from photographers to knowledge workers, with a 10.5% revenue growth rate and a 28.7% profit margin, all while maintaining a 0.53 PEG ratio, indicating that the growth is reasonably priced. This growth persistence is key to the thesis, as it allows ADBE to continuously invest in its products and services, further solidifying its position in the market. The crux of this argument is that ADBE can sustain this growth rate, which is supported by its $10.3b in free cash flow, providing the necessary funds for investments and buybacks.
Moat. Adobe's durable edge comes from its integrated platform in the Digital Experience segment, which enables brands and businesses to manage customer experiences from analytics to commerce. This platform creates a significant switching cost for customers, as it is deeply integrated into their operations, making it difficult for competitors to replicate. Furthermore, ADBE's 62.8% ROE can be attributed to its pricing power from category leadership in the creative and marketing software spaces, allowing it to maintain high margins and invest in further innovation.
Risk. The bear case against ADBE is centered around its high 1.4 beta, indicating a higher volatility compared to the market, and its 0.61 debt-to-equity ratio, which, although not alarming, could become a concern if interest rates rise significantly. Additionally, the concentration of its business in the Digital Media and Digital Experience segments poses a risk if either of these markets experiences a downturn. A concrete signal that would confirm the bear case would be a significant decline in 10.5% revenue growth, indicating that the company is not able to sustain its growth trajectory.
Horizon. 1-3 yr $282.27 (analyst consensus (n=32)) — fundamentals + valuation re-rating. 5 yr $413.27 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $613.06 if current growth sustains into durable earnings power.
5. LRN — Stride, Inc. · score 89.4
Education & Training Services · price $82.98 · 1Y $95.43 · 5Y $139.71 · 10Y $207.26
FCF $414m C · Rev +17.9% B+ · D/E 0.33 A- · P/E 13.0x A- · PEG 0.46 A
Why now. The bull case for LRN rests on its ability to compound growth through its integrated package of systems, services, and products for virtual or blended public schools, with a 17.9% revenue growth rate and a 13 P/E ratio, indicating a 0.46 PEG ratio that suggests undervaluation. This growth is further supported by its $414m in free cash flow, which enables the company to invest in its products and services. The crux of this thesis is that LRN can maintain its growth trajectory, driven by its technology-based products and services that enable individualized learning for students.
Moat. LRN's durable edge stems from its proprietary online curriculum and software systems, which provide a cost advantage and create switching costs for its clients. The company's 18.8% ROE is a result of its pricing power, derived from its category leadership in providing virtual or blended public school solutions. This advantage is difficult for competitors to replicate quickly, as it requires significant investment in technology and educational expertise.
Risk. The bear case against LRN is that its growth may decelerate due to increasing competition in the online education market, which could lead to margin contraction. The company's 0.33 debt-to-equity ratio is relatively low, but its 12.2% profit margin may be at risk if it faces significant pricing pressure. A concrete signal that would confirm the bear case is a decline in revenue growth rate or a decrease in profit margin, which would break the bull thesis.
Horizon. 1-3 yr $95.43 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $139.71 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $207.26 if current growth sustains into durable earnings power.
6. PCTY — Paylocity Holding Corporation · score 89.4
Software - Application · price $100.89 · 1Y $154.16 · 5Y $225.70 · 10Y $334.81
FCF $487m C · Rev +14.8% B+ · D/E 0.11 B+ · P/E 21.6x B+ · PEG 0.78 A-
Why now. The bull case for PCTY rests on its ability to compound growth through its cloud-based human capital management solutions, specifically its payroll and time and attendance offerings, with a 21.6 P/E ratio, 14.8% revenue growth, and $487m in free cash flow, all of which suggest a strong and persistent growth trajectory, hinging on the company's ability to maintain its 16.1% profit margin.
Moat. PCTY's durable edge stems from its comprehensive suite of human capital management solutions, including HR, payroll, and time and attendance, which creates a sticky customer base due to the complexity and integration of these services, as evidenced by its 21.9% ROE, driven by pricing power from category leadership in the workforce management space, making it difficult for competitors to replicate quickly.
Risk. The bear case against PCTY centers on its valuation, with a 21.6 P/E ratio and $5.4b market cap, which may be elevated given the company's 14.8% revenue growth rate, and the risk that growth decelerates or margins contract, potentially triggered by increased competition or a slowdown in the workforce management market, which would be confirmed by a decline in its 16.1% profit margin or a significant increase in its 0.11 debt-to-equity ratio.
Horizon. 1-3 yr $154.16 (analyst consensus (n=19)) — fundamentals + valuation re-rating. 5 yr $225.70 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $334.81 if current growth sustains into durable earnings power.
7. ADMA — ADMA Biologics, Inc. · score 88.8
Biotechnology · price $8.69 · 1Y $17.60 · 5Y $25.77 · 10Y $38.23
1Y -52% D · Rev +19.6% B+ · ROE 42.4% A · FCF $108m C
Why now. The bull case for ADMA Biologics, Inc. rests on its high-margin, high-growth franchise in plasma-derived biologics, driven by products like BIVIGAM and ASCENIV, with a 32.4% profit margin, 19.6% revenue growth, and $108m in free cash flow, all of which suggest a compounding growth story that persists due to its strong position in a niche market.
Moat. ADMA's durable edge comes from its expertise in developing, manufacturing, and marketing specialty plasma-derived biologics, such as Nabi-HB, which provides a high barrier to entry for competitors due to the complexity and cost of establishing plasma collection centers and manufacturing facilities, allowing ADMA to maintain its 42.4% ROE through pricing power and operational efficiency.
Risk. The bear case against ADMA centers on its debt-to-equity ratio of 1.11 and a beta of 0.73, which, although relatively low, still indicates some market risk, particularly if the company faces challenges in its Plasma Collection Centers segment or if there's a downturn in the demand for its products, which could confirm the bear case if ADMA's profit margin begins to contract significantly.
Horizon. 1-3 yr $17.60 (analyst consensus (n=5)) — fundamentals + valuation re-rating. 5 yr $25.77 at ~24% CAGR — compounding case rests on the competitive position widening. 10 yr $38.23 if current growth sustains into durable earnings power.
8. HRMY — Harmony Biosciences Holdings, Inc. · score 87.8
Biotechnology · price $34.16 · 1Y $44.36 · 5Y $64.95 · 10Y $96.35
1Y +4% C+ · Rev +21.5% A- · ROE 16.0% B+ · FCF $342m C
Why now. The bull case for HRMY rests on its ability to compound growth through its novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy, driven by WAKIX (pitolisant), with a 21.5% revenue growth rate, a 13.8 P/E ratio, and $342m in free cash flow, all of which suggest a strong and persistent growth trajectory, hinging on the continued success of its core product and pipeline expansion.
Moat. HRMY's durable edge stems from its 16.2% profit margin, which is likely a result of its pricing power from category leadership in rare neurological diseases, particularly in the treatment of narcolepsy, and its 16% ROE, indicating a strong ability to generate returns on equity, both of which are difficult for competitors to replicate quickly, especially given the company's focus on a specific and complex therapeutic area.
Risk. The bear case against HRMY centers on its 0.97 beta, indicating a high sensitivity to market fluctuations, and its 0.18 debt-to-equity ratio, which, although relatively low, could still pose a risk if the company's growth slows or if it faces significant competition, particularly from other pharmaceutical companies developing treatments for similar rare neurological diseases, with a concrete signal to confirm the bear case being a significant decline in WAKIX sales or a major setback in the company's pipeline expansion.
Horizon. 1-3 yr $44.36 (analyst consensus (n=11)) — fundamentals + valuation re-rating. 5 yr $64.95 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $96.35 if current growth sustains into durable earnings power.
9. NUTX — Nutex Health Inc. · score 87.3
Medical Care Facilities · price $147.23 · 1Y $235.50 · 5Y $344.80 · 10Y $511.48
1Y +30% B+ · Rev +82.4% A · ROE 27.8% A- · FCF $269m C
Why now. The bull case for NUTX rests on its explosive 82.4% revenue growth, driven by the Hospital segment's development of micro hospitals and specialty hospitals, which is further supported by a 10.8 P/E ratio and $269m in free cash flow, all of which compound to create a high-growth, high-return profile that persists due to its 11% profit margin and 27.8% ROE.
Moat. NUTX's durable edge comes from its Population Health Management segment, which provides critical support services to affiliated hospitals and physician groups, creating a network effect that competitors can't quickly replicate, and its 27.8% ROE is a testament to the pricing power derived from category leadership in healthcare services.
Risk. The bear case against NUTX centers on its 2.06 beta, indicating high volatility, and a 0.79 debt-to-equity ratio, which, if not managed properly, could lead to financial distress, especially if the company's 82.4% revenue growth decelerates, confirming the bear thesis and breaking the bull case.
Horizon. 1-3 yr $235.50 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $344.80 at ~19% CAGR — compounding case rests on the competitive position widening. 10 yr $511.48 if current growth sustains into durable earnings power.
10. EXLS — ExlService Holdings, Inc. · score 86.2
Information Technology Services · price $26.16 · 1Y $41.75 · 5Y $61.13 · 10Y $90.68
FCF $297m C · Rev +13.6% B+ · D/E 0.67 C+ · P/E 16.7x A- · PEG 0.82 B+
Why now. The bull case for EXLS rests on its ability to compound growth through its digital operations and solutions, particularly in the Insurance and Healthcare and Life Sciences segments, where it provides claims management, premium and benefit administration, and analytics-driven services. With a PEG ratio of 0.82, revenue growth of 13.6%, and profit margin of 11.7%, EXLS is well-positioned to sustain its growth trajectory, driven by its expertise in data and artificial intelligence. The crux of this thesis is that EXLS can maintain its FCF of $297m while expanding its services into new markets.
Moat. EXLS's durable edge lies in its analytics-driven services, particularly in the Insurance segment, where its actuarial and risk analytics capabilities provide a significant competitive advantage. The company's ROE of 32.3% is a testament to its pricing power, driven by its category leadership in data and AI services. This advantage is difficult for competitors to replicate quickly, as it requires significant investments in technology and talent, making EXLS's moat relatively durable.
Risk. The bear case for EXLS centers around its debt-to-equity ratio of 0.67, which, although manageable, could become a concern if interest rates rise or the company's growth slows. Additionally, the company's beta of 0.82 indicates that it is less volatile than the market, but still susceptible to broader market fluctuations. If EXLS's revenue growth were to decelerate significantly, its valuation multiples could contract, confirming the bear case and breaking the bull thesis.
Horizon. 1-3 yr $41.75 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $61.13 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $90.68 if current growth sustains into durable earnings power.
11. NVDA — NVIDIA Corporation · score 86.2
Semiconductors · price $200.04 · 1Y $298.93 · 5Y $437.67 · 10Y $649.25
1Y +41% A- · Rev +65.5% A · ROE >100% A · FCF $119.1b A
Why now. NVIDIA Corporation is a compelling growth investment due to its dominance in the data center scale AI infrastructure market, driven by its Compute & Networking segment, which has fueled a 65.5% revenue growth rate and a 63% profit margin. With a $119.1b free cash flow and a 0.64 PEG ratio, the company is well-positioned to compound its growth. The crux of this thesis rests on the company's ability to maintain its 81.7% ROE, driven by its pricing power in the AI infrastructure market.
Moat. NVIDIA's durable edge is its category leadership in the data center accelerated computing and networking platforms, which creates a high switching cost for its customers. The company's 63% profit margin is a result of its pricing power, driven by its strong position in the AI infrastructure market. This moat is further protected by the company's significant investments in research and development, which has enabled it to maintain its technological edge.
Risk. The strongest argument against NVIDIA is the risk of a slowdown in the data center market, which could impact the company's 65.5% revenue growth rate. With a 30.6 P/E ratio and a 2.2 beta, the stock is not cheap, and any deceleration in growth could lead to a significant correction. A concrete signal that would confirm the bear case is a decline in the company's $119.1b free cash flow, which would indicate a slowdown in the company's ability to generate cash and invest in its growth initiatives.
Horizon. 1-3 yr $298.93 (analyst consensus (n=59)) — fundamentals + valuation re-rating. 5 yr $437.67 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $649.25 if current growth sustains into durable earnings power.
12. FISV — Fiserv, Inc. · score 85.4
Sector n/a · price $47.30 · 1Y $70.00 · 5Y $102.49 · 10Y $152.03
FCF $4.1b B · Rev +9.3% B · D/E n/a · P/E 8.0x A- · PEG n/a
Why now. The bull case for FISV rests on its ability to compound growth through its 9.3% revenue growth rate, driven by its $4.1B in free cash flow and a 19.7% profit margin, which enables the company to reinvest in its business and drive long-term expansion. This growth trajectory is further supported by the company's $25.2B market capitalization, which provides a solid foundation for future growth. The crux of this thesis is the company's ability to maintain its 9.3% revenue growth rate, which is critical to driving long-term value creation.
Moat. FISV's durable edge is rooted in its 12.2% return on equity, which is driven by its ability to generate high profits from its core business. This is attributed to the company's 19.7% profit margin, which is a result of its pricing power and efficient operations. Additionally, the company's $4.1B in free cash flow provides a significant advantage, as it allows the company to invest in its business and drive growth, making it difficult for competitors to replicate.
Risk. The bear case for FISV is centered around the company's 8 price-to-earnings ratio, which may be elevated given the company's growth prospects. Furthermore, the company's 47.3 current price is near its 47.04 52-week low, which may indicate a lack of momentum in the stock. If the company's revenue growth rate were to decelerate, it could confirm the bear case and break the bull thesis, as it would indicate that the company's growth trajectory is not sustainable.
Horizon. 1-3 yr $70.00 (analyst consensus (n=26)) — fundamentals + valuation re-rating. 5 yr $102.49 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $152.03 if current growth sustains into durable earnings power.
13. CARG — CarGurus, Inc. · score 85
Auto & Truck Dealerships · price $30.44 · 1Y $37.38 · 5Y $54.73 · 10Y $81.20
FCF $293m C · Rev +13.7% B+ · D/E 0.79 B · P/E 16.0x B+ · PEG 0.91 B+
Why now. The bull case for CarGurus, Inc. rests on its ability to compound growth through its online automotive marketplace, specifically driven by its Digital Deal and Dealership Mode products, with a PEG ratio of 0.91, revenue growth of 13.7%, and a profit margin of 15.9%, all of which suggest a high-quality growth franchise that can persist, but it all hinges on the company's ability to maintain its 62.9% ROE.
Moat. CarGurus' durable edge is its extensive network of dealers and large audience of car shoppers, which creates a network effect that makes it harder for competitors to replicate, and its roe_pct of 62.9% is a testament to its pricing power from category leadership in the online automotive marketplace, which is further reinforced by its debt_to_equity of 0.79, indicating a healthy balance sheet.
Risk. The bear case against CarGurus, Inc. is that its beta of 1.21 and pe_ttm of 16 may indicate a valuation that is sensitive to market fluctuations and potentially overvalued, and if the company's revenue growth pct starts to decelerate, it could confirm the bear case and break the bull thesis, especially if the analyst_consensus_1yr_target of $37.38 is not met.
Horizon. 1-3 yr $37.38 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $54.73 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $81.20 if current growth sustains into durable earnings power.
14. IT — Gartner, Inc. · score 84.5
Information Technology Services · price $129.18 · 1Y $166.54 · 5Y $243.83 · 10Y $361.70
FCF $1.3b C+ · Rev +3.7% C+ · D/E n/a · P/E 12.8x A- · PEG 0.51 A-
Why now. The bull case for Gartner, Inc. rests on its ability to compound growth through its Insights segment, which delivers high-margin, subscription-based research and access to experts, as evidenced by its 12.8 price-to-earnings ratio, 0.51 PEG ratio, and 11.4% profit margin. This, combined with its $1.3b in free cash flow and 3.7% revenue growth, positions the company for sustained expansion. The crux of this thesis hinges on Gartner's capacity to maintain its competitive edge in the research and advisory space.
Moat. Gartner's durable edge stems from its extensive network of business and technology experts, which provides a unique value proposition to its clients, particularly through its Research segment. This expertise, coupled with its data and benchmarks, creates a high switching cost for clients, making it difficult for competitors to replicate. The company's 0.93 beta further indicates a relatively stable market position, suggesting that its competitive advantage is not easily eroded.
Risk. The bear case against Gartner, Inc. centers on its dependence on the Insights segment for growth and the potential for disruption in the research and advisory market. With an analyst recommendation of 'hold' and a 2.73 mean recommendation score, there is skepticism about the company's ability to significantly outperform. A concrete signal that would confirm the bear case would be a decline in revenue growth or a failure to maintain its profit margin, indicating that the company's competitive edge is weakening.
Horizon. 1-3 yr $166.54 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $243.83 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $361.70 if current growth sustains into durable earnings power.
15. EPAM — EPAM Systems, Inc. · score 83.8
Information Technology Services · price $76.89 · 1Y $144.06 · 5Y $210.91 · 10Y $312.87
FCF $544m C+ · Rev +15.4% B+ · D/E 0.08 B+ · P/E 11.0x A · PEG 0.39 A
Why now. The bull case for EPAM Systems, Inc. rests on its ability to compound growth through its digital platform engineering and software development services, with a 15.4% revenue growth rate and a 0.39 PEG ratio indicating undervaluation. This growth is further supported by its $544m in free cash flow, demonstrating the company's ability to generate cash and invest in its business. The crux of this thesis is that EPAM's growth will persist due to its strong position in the digital transformation market.
Moat. EPAM's durable edge is its expertise in engineering services, including requirements analysis and platform selection, customization, and integration, which creates a high switching cost for its clients. Additionally, its 11.3% ROE is a result of its pricing power in the market, driven by its category leadership in digital platform engineering. This advantage is difficult for competitors to replicate quickly, as it requires significant investment in talent and technology.
Risk. The bear case against EPAM is that its high 1.4 beta indicates a higher volatility in its stock price, which could be a concern for investors. Additionally, the company's 0.08 debt-to-equity ratio, while low, could increase if the company takes on more debt to finance its growth initiatives. A concrete signal that would confirm the bear case is if EPAM's revenue growth rate slows down significantly, indicating that the company is losing its competitive edge.
Horizon. 1-3 yr $144.06 (analyst consensus (n=18)) — fundamentals + valuation re-rating. 5 yr $210.91 at ~22% CAGR — compounding case rests on the competitive position widening. 10 yr $312.87 if current growth sustains into durable earnings power.
16. VEEV — Veeva Systems Inc. · score 83.3
Health Information Services · price $159.71 · 1Y $245.48 · 5Y $359.41 · 10Y $533.16
FCF $1.7b C+ · Rev +16.3% B+ · D/E 0.01 A- · P/E 28.3x C+ · PEG 0.69 A-
Why now. The bull case for VEEV rests on its ability to compound growth through its cloud-based software offerings, specifically Veeva Commercial Cloud, which has driven a 16.3% revenue growth rate and a 28.4% profit margin. With a PEG ratio of 0.69, the stock is reasonably valued given its growth prospects. The crux of this thesis is that VEEV can maintain its 28.3 P/E ratio by continuing to deliver strong top-line growth and expanding its profit margins, fueled by the adoption of its Veeva Vault CRM Suite and Veeva Medical products.
Moat. VEEV's durable edge stems from its Veeva Data Cloud, which provides a comprehensive customer reference data solution through Veeva OpenData, creating a switching cost for its life sciences customers. Additionally, its Veeva Link and Veeva Compass products offer deep data insights, making it difficult for competitors to replicate. This moat is further reinforced by VEEV's 12.9% ROE, driven by its pricing power from category leadership in the life sciences industry.
Risk. The bear case against VEEV centers on its elevated P/E of 28.3, which may be unsustainable if the company's revenue growth decelerates. A specific threat is the potential for a decline in demand for its Veeva Commercial Cloud products, driven by a downturn in the life sciences industry. If VEEV's revenue growth rate were to slow significantly, its debt-to-equity ratio of 0.01 would become less relevant, and the stock's valuation multiple could contract, confirming the bear case.
Horizon. 1-3 yr $245.48 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $359.41 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $533.16 if current growth sustains into durable earnings power.
17. DXCM — DexCom, Inc. · score 82.9
Medical Devices · price $68.92 · 1Y $85.21 · 5Y $124.75 · 10Y $185.06
1Y -21% D · Rev +15.6% B+ · ROE 31.5% A · FCF $1.4b C+
Why now. The bull case for DXCM rests on the persistent compounding of its high-quality CGM systems, specifically the Dexcom G7 and G7 15 Day, which drive a $1.4B free cash flow against a $26.6B market cap, with a 15.6% revenue growth rate and a 29.6 P/E ratio, all of which underpin the $85.21 1-yr target; the crux is whether this growth can persist given the 1.29 PEG ratio.
Moat. DXCM's durable edge stems from its integrated continuous glucose monitoring systems like Dexcom G7, which commands a 31.5% ROE due to pricing power from category leadership in CGM, a moat that competitors can't quickly replicate due to the high switching costs for diabetics and the network effects from its remote monitoring systems like Dexcom Share.
Risk. The bear case against DXCM centers on its 1.44 beta and 0.47 debt-to-equity ratio, signaling potential volatility and financial risk, especially if the 15.6% revenue growth decelerates, which could confirm the bear case if the $65–$112 analyst target range contracts, breaking the bull thesis.
Horizon. 1-3 yr $85.21 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $124.75 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $185.06 if current growth sustains into durable earnings power.
18. RMD — ResMed Inc. · score 82.7
Medical Instruments & Supplies · price $191.26 · 1Y $260.60 · 5Y $381.54 · 10Y $566.00
1Y -26% D · Rev +9.8% B · ROE 23.4% A- · FCF $1.8b C+
Why now. ResMed Inc. is a compelling growth story driven by its Sleep and Breathing Health segment, where products like ApneaLink Air and NightOwl are poised to capitalize on the growing demand for sleep apnea diagnosis and treatment, with a profit margin of 27.4%, revenue growth of 9.8%, and a PEG ratio of 1.11, all of which suggest the company's growth is not only strong but also reasonably valued, resting on the crux of sustained innovation in its sleep health offerings.
Moat. ResMed's durable edge stems from its category leadership in sleep health, where its products like ApneaLink Air enjoy pricing power due to their clinical efficacy and ease of use, contributing to an ROE of 23.4%, which is a result of the company's ability to maintain high margins through a combination of innovative products and a strong distribution network, making it difficult for competitors to quickly replicate its success.
Risk. The bear case against ResMed centers on the potential for increased competition in the sleep health market, particularly from lower-cost diagnostic devices, which could erode profit margins of 27.4% and challenge the company's debt-to-equity ratio of 0.13, a signal that would confirm the bear case is if ResMed's revenue growth begins to decelerate significantly, failing to meet its 9.8% growth rate, indicating that competitors are gaining traction.
Horizon. 1-3 yr $260.60 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $381.54 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $566.00 if current growth sustains into durable earnings power.
19. YELP — Yelp Inc. · score 82.2
Internet Content & Information · price $22.67 · 1Y $26.50 · 5Y $38.80 · 10Y $57.56
FCF $281m C · Rev +3.7% C+ · D/E 0.25 A- · P/E 10.4x A- · PEG 0.57 A-
Why now. YELP's 10.4 P/E ratio and 0.57 PEG ratio make it an attractive growth compounder, driven by its cost-per-click advertising and multi-location Ad products, with $281m in free cash flow and 3.7% revenue growth, resting on the crux of its ability to maintain this growth trajectory.
Moat. YELP's durable edge comes from its 22% ROE, driven by pricing power from category leadership in local business advertising, particularly through its Yelp Connect product, which provides a unique channel for advertisers to market new offerings and communicate business updates, making it difficult for competitors to quickly replicate.
Risk. The bear case against YELP is led by its 0.25 debt-to-equity ratio, which, although relatively low, could still pose a risk if the company fails to maintain its revenue growth, and its 0.47 beta, indicating a potential for significant stock price volatility, with a concrete signal being a decline in its 9.5% profit margin, which would confirm the bear case and break the bull thesis.
Horizon. 1-3 yr $26.50 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $38.80 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $57.56 if current growth sustains into durable earnings power.
20. META — Meta Platforms, Inc. · score 82.1
Internet Content & Information · price $562.20 · 1Y $827.32 · 5Y $1,211 · 10Y $1,797
FCF $48.3b A · Rev +22.2% A- · D/E 0.36 B+ · P/E 20.4x B · PEG 0.81 B+
Why now. The bull case for META rests on its ability to compound growth through its Family of Apps (FoA) segment, which includes Facebook, Instagram, and Messenger, with a 22.2% revenue growth rate and a 20.4 P/E ratio that is reasonable for a growth name, driven by a 32.8% profit margin. This growth persistence is key to the thesis. The crux is whether META can maintain its revenue growth trajectory.
Moat. META's durable edge comes from its network effects across its FoA segment, particularly Facebook and Instagram, where users attract more users, creating a self-reinforcing cycle that competitors struggle to replicate. The 29% ROE is a testament to the pricing power from category leadership in social media, which allows META to maintain high margins.
Risk. The bear case against META centers on its high 1.23 beta, indicating volatility, and a 0.36 debt-to-equity ratio that, while not alarming, suggests a potential for increased financial leverage. If META's revenue growth decelerates significantly, the bull thesis would be at risk, particularly if the company fails to navigate the competitive landscape effectively.
Horizon. 1-3 yr $827.32 (analyst consensus (n=59)) — fundamentals + valuation re-rating. 5 yr $1,211 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $1,797 if current growth sustains into durable earnings power.
21. CVSA — Covista Inc. · score 82
Education & Training Services · price $120.73 · 1Y $156.25 · 5Y $228.77 · 10Y $339.36
FCF $336m C · Rev +12.9% B+ · D/E 0.54 B+ · P/E 17.6x B · PEG 0.88 B+
Why now. Covista Inc.'s growth is driven by its Chamberlain, Walden, and Medical and Veterinary segments, with a strong focus on healthcare education, which is a high-growth area. With a PEG ratio of 0.88, revenue growth of 12.9%, and a profit margin of 12.3%, the company is well-positioned for continued expansion. The crux of the thesis rests on the company's ability to maintain its growth trajectory in the healthcare education space.
Moat. Covista's durable edge comes from its established position in the healthcare education market, with a strong portfolio of degree and non-degree programs, including nursing, health professions, and medical education. The company's ROE of 17.2% is a result of its pricing power and cost advantages, driven by its category leadership in healthcare education. This moat is protected by the company's strong reputation and the high switching costs for students and faculty.
Risk. The bear case for Covista is centered around the company's debt-to-equity ratio of 0.54, which, while manageable, could become a concern if the company's growth slows or if interest rates rise. Additionally, the company's beta of 0.62 indicates a relatively low level of volatility, but the P/E of 17.6 is not excessively high, given the company's growth prospects. A concrete signal that would confirm the bear case would be a significant decline in revenue growth or a increase in debt levels.
Horizon. 1-3 yr $156.25 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $228.77 at ~14% CAGR — compounding case rests on the competitive position widening. 10 yr $339.36 if current growth sustains into durable earnings power.
22. MELI — MercadoLibre, Inc. · score 82
Internet Retail · price $1583.66 · 1Y $2,217 · 5Y $3,246 · 10Y $4,815
1Y -37% D · Rev +34.3% A · ROE 26.4% A- · FCF $11.8b A-
Why now. MercadoLibre's 34.3% revenue growth rate, combined with its $11.8b in free cash flow and 41.9 P/E ratio, positions the company for sustained compounding, driven by the expansion of its Mercado Pago financial technology solution platform and Mercado Libre Marketplace. This growth persists due to the company's ability to leverage its existing user base and provide a comprehensive set of financial services, ultimately resting on its capacity to maintain a 26.4% return on equity.
Moat. MercadoLibre's durable edge is rooted in its Mercado Pago platform, which offers a range of financial services to users, creating a network effect that enhances the value proposition for both buyers and sellers on the Mercado Libre Marketplace. The company's 26.4% return on equity is a testament to its pricing power, derived from its category leadership in Latin American e-commerce and financial services. This advantage is difficult for competitors to replicate quickly, given the scale and breadth of MercadoLibre's ecosystem.
Risk. The primary threat to MercadoLibre's growth trajectory is the potential for increased competition in the Latin American e-commerce and financial services markets, which could erode the company's 8.6% profit margin. Additionally, the company's 1.7 debt-to-equity ratio and 1.35 beta indicate a degree of financial leverage and market sensitivity, which could amplify losses if the business experiences a downturn. A concrete signal that would confirm the bear case is a significant decline in revenue growth or a contraction in profit margins, which would undermine the bull thesis.
Horizon. 1-3 yr $2,217 (analyst consensus (n=24)) — fundamentals + valuation re-rating. 5 yr $3,246 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $4,815 if current growth sustains into durable earnings power.
23. PRDO — Perdoceo Education Corporation · score 81.4
Education & Training Services · price $32.72 · 1Y $37.63 · 5Y $55.09 · 10Y $81.72
FCF $225m C · Rev +24.2% A- · D/E 0.12 A- · P/E 12.5x A- · PEG 0.70 A-
Why now. Perdoceo Education Corporation's growth thesis rests on its ability to compound earnings through its high-margin postsecondary education programs, particularly in the career-oriented disciplines of business and management, nursing, and healthcare management, with a 19.9% profit margin, 24.2% revenue growth, and a 0.7 PEG ratio indicating undervaluation. This growth is driven by its Colorado Technical University (CTU), The American InterContinental University System (AIUS), and University of St. Augustine for Health Sciences (USAHS) segments. The crux of this thesis is the persistence of this earnings growth, driven by the demand for online and blended learning programs.
Moat. Perdoceo's durable edge comes from its established position in the postsecondary education market, with a strong track record of providing career-oriented programs that meet the needs of employers, thereby creating a switching cost for students and a network effect as more employers recognize the value of its graduates. The 17% ROE is a testament to the company's ability to maintain pricing power in its niche, particularly in the CTU segment, which offers a range of programs in business, nursing, and healthcare management.
Risk. The bear case against Perdoceo Education Corporation centers on the risk of regulatory changes affecting the postsecondary education industry, potentially impacting the company's ability to maintain its profit margins and growth rate. With a 12.5 P/E ratio, the stock may be vulnerable to multiple compression if growth decelerates or if regulatory risks materialize, such as increased scrutiny over for-profit education institutions. A concrete signal that would confirm the bear case would be a decline in enrollment rates or a significant increase in regulatory costs.
Horizon. 1-3 yr $37.63 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $55.09 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $81.72 if current growth sustains into durable earnings power.
24. EPAC — Enerpac Tool Group Corp. · score 79.6
Specialty Industrial Machinery · price $35.38 · 1Y $40.69 · 5Y $59.57 · 10Y $88.37
FCF $111m C · Rev +4.6% C+ · D/E 0.46 B+ · P/E 22.3x B+ · PEG 0.34 A
Why now. The bull case for EPAC rests on its ability to compound growth through its highly engineered heavy lifting technology solutions, with a PEG ratio of 0.34 indicating undervaluation given its 4.6% revenue growth and 13.7% profit margin, all of which suggest the company can persist in delivering returns above its cost of capital, with the crux being whether it can maintain its 21% ROE in the face of competition.
Moat. EPAC's durable edge stems from its branded hydraulic and mechanical tools, particularly its highly engineered heavy lifting technology solutions, which provide a cost advantage through their efficiency and reliability, allowing the company to maintain its 21% ROE through pricing power derived from its category leadership in industrial maintenance and repair operations, a moat that competitors cannot quickly replicate due to the high switching costs for customers.
Risk. The bear case against EPAC centers on its debt-to-equity ratio of 0.46 and a beta of 0.87, indicating potential volatility and sensitivity to market downturns, with the specific threat being a decline in infrastructure and industrial spending that could contract EPAC's 4.6% revenue growth and increase its debt burden, confirming the bear case if the company's profit margin begins to contract significantly.
Horizon. 1-3 yr $40.69 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $59.57 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $88.37 if current growth sustains into durable earnings power.
25. FIVE — Five Below, Inc. · score 78.9
Specialty Retail · price $185.95 · 1Y $261.57 · 5Y $382.97 · 10Y $568.11
FCF $505m C+ · Rev +22.9% A- · D/E 0.86 B · P/E 23.4x B · PEG 0.98 B+
Why now. The bull case for Five Below, Inc. rests on its ability to compound growth through its assortment of classic and novelty candy bars, movie-size box candy, and seasonal-related candy, with a 22.9% revenue growth rate and a 23.4 P/E ratio that is justified by its 8.7% profit margin. This growth is driven by the company's ability to offer a wide range of products at a low price point, making it an attractive destination for price-conscious consumers. The crux of this thesis is that Five Below can maintain its revenue growth rate while expanding its profit margin, driven by its strong product offerings and efficient operations.
Moat. Five Below's durable edge is its ability to offer a unique and constantly changing assortment of products, including personalized living space products, party goods, and decorations, which creates a treasure hunt experience for customers and drives repeat business. This is evidenced by the company's 19% ROE, which is driven by its pricing power and ability to maintain high margins. Additionally, the company's 0.86 debt-to-equity ratio provides a stable financial foundation for the company to continue to invest in its operations and drive growth.
Risk. The bear case for Five Below is that the company's growth may slow due to increased competition from online retailers and other discount stores, which could pressure the company's 8.7% profit margin and 22.9% revenue growth rate. Additionally, the company's 0.97 beta indicates that it is highly correlated with the overall market, making it vulnerable to market downturns. If the company's revenue growth rate were to slow significantly, it could confirm the bear case and break the bull thesis.
Horizon. 1-3 yr $261.57 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $382.97 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $568.11 if current growth sustains into durable earnings power.
26. HURN — Huron Consulting Group Inc. · score 78
Consulting Services · price $95.54 · 1Y $184.25 · 5Y $269.76 · 10Y $400.17
1Y -33% D · Rev +11.7% B · ROE 26.1% A- · FCF $124m C
Why now. The bull case for HURN rests on its ability to compound growth through its Healthcare, Education, and Commercial segments, with a specific driver being its digital services, including technology and analytic-related services, which has led to a revenue growth of 11.7% and a profit margin of 5.9%, all while maintaining a PEG ratio of 1.47. This growth persistence is crucial as it underpins the thesis. The crux of this argument hinges on HURN's capacity to sustain this growth trajectory, particularly in its Healthcare segment.
Moat. HURN's durable edge stems from its expertise in enterprise health record, enterprise resource planning, and enterprise performance management, which creates switching costs for its clients and protects its 26.1% ROE. This high ROE is a result of pricing power from category leadership in its segments, particularly in the Healthcare space, where its consulting services provide significant value to clients. This moat is further reinforced by the company's ability to provide a portfolio of software products, making it a one-stop-shop for its clients.
Risk. The bear case against HURN is centered around its high debt-to-equity ratio of 2.24, which poses a significant risk, especially if interest rates rise. Additionally, the company's beta of 0.09 might suggest a lower volatility, but the bear would argue that this could turn against the company if its segments, particularly Healthcare, experience a downturn. The concrete signal that would confirm the bear case is a significant decline in revenue growth, which would break the bull thesis and suggest that HURN's growth is not as persistent as thought.
Horizon. 1-3 yr $184.25 (analyst consensus (n=4)) — fundamentals + valuation re-rating. 5 yr $269.76 at ~23% CAGR — compounding case rests on the competitive position widening. 10 yr $400.17 if current growth sustains into durable earnings power.
27. DV — DoubleVerify Holdings, Inc. · score 77.7
Advertising Agencies · price $10.44 · 1Y $13.06 · 5Y $19.12 · 10Y $28.36
1Y -31% D · Rev +13.9% B+ · ROE 5.1% C+ · FCF $135m C
Why now. The bull case for DoubleVerify Holdings, Inc. rests on its ability to compound growth through its media effectiveness platforms, specifically the 13.9% revenue growth rate and $135m in free cash flow, which demonstrates the company's ability to scale its business while maintaining a 7.2% profit margin. This growth is driven by its DV Authentic Ad and DV Authentic Attention products, which provide a unique value proposition to advertisers. The crux of this thesis is that DoubleVerify can sustain this growth rate, driven by its innovative products and expanding customer base.
Moat. DoubleVerify's durable edge is its ability to provide high-quality, fraud-free digital ad inventory to advertisers, which is protected by its proprietary technology and data analytics capabilities, such as its Custom Contextual solution and Scibids AI. This edge is further reinforced by its 5.1% return on equity, which is driven by its ability to maintain high margins and efficiently allocate capital. A competitor would struggle to replicate this advantage quickly, given the complexity and specificity of DoubleVerify's technology and data assets.
Risk. The bear case against DoubleVerify is that its high 31.6 price-to-earnings ratio and 2.1 price-to-sales ratio may be unsustainable, particularly if the company's revenue growth rate decelerates. Additionally, the company's 0.99 beta indicates that its stock price may be highly volatile, which could lead to significant downside risk if the market experiences a downturn. A concrete signal that would confirm the bear case is if DoubleVerify's revenue growth rate were to slow significantly, causing its valuation multiples to contract.
Horizon. 1-3 yr $13.06 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $19.12 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $28.36 if current growth sustains into durable earnings power.
28. WLDN — Willdan Group, Inc. · score 77.6
Engineering & Construction · price $82.29 · 1Y $94.63 · 5Y $138.55 · 10Y $205.53
FCF $43m C- · Rev +20.5% A- · D/E 0.22 A- · P/E 22.1x B+ · PEG 0.48 A
Why now. The bull case for WLDN rests on its ability to compound growth through its Energy segment, which offers comprehensive audit and surveys, program design and implementation, and software and data analytics, driven by its 20.5% revenue growth, 22.1 P/E ratio, and 0.48 PEG ratio, all of which suggest a high-quality growth compounder with a reasonable valuation, and it all hinges on the company's ability to sustain its 8.2% profit margin
Moat. WLDN's durable edge comes from its expertise in energy efficiency and grid optimization, where its software and data analytics capabilities provide a cost advantage and high switching costs for its customers, as evidenced by its 18.2% ROE, which is driven by pricing power from its category leadership in the Energy segment, making it difficult for competitors to replicate its business model
Risk. The bear case against WLDN is that its 1.11 beta and 0.22 debt-to-equity ratio may make it vulnerable to market downturns and interest rate increases, and if the company's revenue growth decelerates or its profit margin contracts, the stock could be at risk of a significant decline, with a key signal being a drop in its 20.5% revenue growth rate
Horizon. 1-3 yr $94.63 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $138.55 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $205.53 if current growth sustains into durable earnings power.
29. DECK — Deckers Outdoor Corporation · score 77.5
Footwear & Accessories · price $103.63 · 1Y $126.86 · 5Y $185.73 · 10Y $275.52
FCF $1.1b C+ · Rev +9.8% B · D/E 0.15 A · P/E 14.8x B+ · PEG 1.31 B
Why now. The bull case for DECK rests on the compounding growth of its high-performance footwear brands, particularly HOKA, which has been driving revenue growth of 9.8% YoY. With a PEG ratio of 1.31, profit margin of 18.7%, and FCF of $1.1B, DECK's growth trajectory is well-supported by its financials, and the crux of this thesis is that HOKA's strong brand momentum will continue to propel the company's top-line expansion.
Moat. DECK's durable competitive advantage stems from its strong brand portfolio, including UGG and HOKA, which have significant pricing power due to their category leadership in the high-performance footwear market. The company's ROE of 41% is a testament to its ability to maintain premium pricing, and this advantage is further reinforced by the high switching costs for customers who invest in DECK's premium products, making it difficult for competitors to quickly replicate its success.
Risk. The bear case against DECK centers on the potential for decelerating growth, particularly if the high-performance footwear market becomes increasingly saturated. With a debt-to-equity ratio of 0.15 and a beta of 1.15, DECK's financials are relatively stable, but a slowdown in revenue growth could lead to multiple compression, and the concrete signal that would confirm this bear case is a significant decline in same-store sales or a failure to meet analyst expectations, which could break the bull thesis and send the stock price downward.
Horizon. 1-3 yr $126.86 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $185.73 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $275.52 if current growth sustains into durable earnings power.
30. NFLX — Netflix, Inc. · score 76.6
Entertainment · price $72.82 · 1Y $114.15 · 5Y $167.12 · 10Y $247.91
1Y -43% D · Rev +15.9% B+ · ROE 43.0% A · FCF $11.9b A-
Why now. The bull case for NFLX rests on its ability to compound growth through its television series and feature films offerings, with a 15.9% revenue growth rate and a 23.5 P/E ratio that is supported by its $11.9B in free cash flow, indicating a strong and sustainable business model. This growth is driven by its ability to provide streaming content through various devices, making it a leader in the entertainment industry. The crux of this thesis is that NFLX can maintain its 28.5% profit margin, which is essential for its long-term success.
Moat. NFLX's durable edge is its ability to provide a wide range of content, including TV series, documentaries, and feature films, across various genres and languages, which creates a significant switching cost for its members. Its 43% ROE is a result of its pricing power, driven by its category leadership in the streaming industry, making it difficult for competitors to replicate its business model. This moat is further strengthened by its ability to distribute content through various devices, making it a leader in the entertainment industry.
Risk. The bear case for NFLX is that its high 1.49 beta and 0.54 debt-to-equity ratio make it vulnerable to market volatility and increased borrowing costs. Additionally, its 71.81 52-week low indicates that the stock has experienced significant price fluctuations, which could be a concern for investors. If NFLX's revenue growth rate were to decline, it could confirm the bear case and break the bull thesis, making its current 23.5 P/E ratio unsustainable.
Horizon. 1-3 yr $114.15 (analyst consensus (n=44)) — fundamentals + valuation re-rating. 5 yr $167.12 at ~18% CAGR — compounding case rests on the competitive position widening. 10 yr $247.91 if current growth sustains into durable earnings power.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.